Bristol Myers Squibb saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 90 to 93.
This exclusive rating from Investor's Business Daily tracks price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners often have an 80 or higher RS Rating at the beginning of a new climb.
How To Use Stock Charts To Stay Profitable And Protected
Bristol Myers Squibb is in a buy range after moving past a 61.10 buy point in a flat base. The proper buying range is up to 5% above the initial entry. Once a stock hits that benchmark, it's best to hold off investing and wait for it to set up another buying opportunity..
The company showed -2% EPS growth last quarter, while sales growth came in at 8%.
The company earns the No. 6 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR, Phibro Animal Health and Protagonist Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
